Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

ConclusionsMOV was characterized by important variability in drug exposure among patients. However, and despite being all heavily pre-treated, 73% of disease control rate and 11 weeks PFS were achieved with manageable toxicities. PK/PD relationships yielded conflicting results depending on the initial tumor burden and BSA, suggesting that patients should be carefully selected prior to be scheduled for metronomic regimen. Possible role NLR could play as a predictive marker suggests immunomodulating features with MOV.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research